Details of the Drug

General Information of Drug (ID: DM4BDON)

Drug Name

Methylprednisolone

Synonyms

Depo-medrol; M-predrol; Medrol; Medrol Acetate

Indication

Disease Entry	ICD 11	Status	REF
Solid tumour/cancer	2A00-2F9Z	Approved	[1]
Spinal cord injury	ND51.2	Investigative	[2]

Therapeutic Class

Anticancer Agents

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

#Ro5 Violations (Lipinski): 0

Molecular Weight (mw)

374.5

Topological Polar Surface Area (xlogp)

1.9

Rotatable Bond Count (rotbonds)

Hydrogen Bond Donor Count (hbonddonor)

Hydrogen Bond Acceptor Count (hbondacc)

ADMET Property

BDDCS Class: Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 1: high solubility and high permeability [3]
Bioavailability: 82% of drug becomes completely available to its intended biological destination(s) [4]
Clearance: The drug present in the plasma can be removed from the body at the rate of 6.1 mL/min/kg [5]
Elimination: 4.9% of drug is excreted from urine in the unchanged form [3]
Half-life: The concentration or amount of drug in body reduced by one-half in 2.3 hours [5]
MRTD: The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 11.1354 micromolar/kg/day [6]
Unbound Fraction: The unbound fraction of drug in plasma is 0.23% [5]
Vd: Fluid volume that would be required to contain the amount of drug present in the body at the same concentration as in the plasma 1.2 L/kg [5]
Water Solubility: The ability of drug to dissolve in water is measured as 0.3236 mg/mL [3]

Chemical Identifiers

Formula: C22H30O5
IUPAC Name: (6S,8S,9S,10R,11S,13S,14S,17R)-11,17-dihydroxy-17-(2-hydroxyacetyl)-6,10,13-trimethyl-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthren-3-one
Canonical SMILES: C[C@H]1C[C@H]2[C@@H]3CC[C@@]([C@]3(C[C@@H]([C@@H]2[C@@]4(C1=CC(=O)C=C4)C)O)C)(C(=O)CO)O
InChI: InChI=1S/C22H30O5/c1-12-8-14-15-5-7-22(27,18(26)11-23)21(15,3)10-17(25)19(14)20(2)6-4-13(24)9-16(12)20/h4,6,9,12,14-15,17,19,23,25,27H,5,7-8,10-11H2,1-3H3/t12-,14-,15-,17-,19+,20-,21-,22-/m0/s1
InChIKey: VHRSUDSXCMQTMA-PJHHCJLFSA-N

Cross-matching ID

PubChem CID: 6741
ChEBI ID: CHEBI:6888
CAS Number: 83-43-2
DrugBank ID: DB00959
TTD ID: D08PIQ
VARIDT ID: DR00128
INTEDE ID: DR1056
ACDINA ID: D00420

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Glucocorticoid receptor (NR3C1)	TTYRL6O	GCR_HUMAN	Modulator	[7]

------------------------------------------------------------------------------------

Drug Transporter (DTP)

DTP Name	DTP ID	UniProt ID	MOA	REF
P-glycoprotein 1 (ABCB1)	DTUGYRD	MDR1_HUMAN	Substrate	[8]

------------------------------------------------------------------------------------

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
Cytochrome P450 3A4 (CYP3A4)_{Main DME}	DE4LYSA	CP3A4_HUMAN	Substrate	[9]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease

Solid tumour/cancer

ICD Disease Classification

2A00-2F9Z

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
P-glycoprotein 1 (ABCB1)	DTP	P-GP	7.23E-01	-8.20E-02	-3.22E-01
Cytochrome P450 3A4 (CYP3A4)	DME	CYP3A4	9.85E-01	2.24E-02	7.33E-02

Molecular Expression Atlas (MEA)

MEA Detail

Jump to Detail Molecular Expression Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Methylprednisolone

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Disease	REF
Larotrectinib	DM26CQR	Moderate	Decreased metabolism of Methylprednisolone caused by Larotrectinib mediated inhibition of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[32]
Armodafinil	DMGB035	Minor	Increased metabolism of Methylprednisolone caused by Armodafinil mediated induction of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[33]
LEE011	DMMX75K	Moderate	Decreased metabolism of Methylprednisolone caused by LEE011 mediated inhibition of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[34]
-----------

Coadministration of a Drug Treating the Disease Different from Methylprednisolone (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Sodium bicarbonate	DMMU6BJ	Minor	Decreased absorption of Methylprednisolone due to altered gastric pH caused by Sodium bicarbonate.	Acidosis [5C73]	[35]
Posaconazole	DMUL5EW	Major	Decreased metabolism of Methylprednisolone caused by Posaconazole mediated inhibition of CYP450 enzyme.	Aspergillosis [1F20]	[36]
Levalbuterol	DM5YBO1	Minor	Increased risk of hypokalemia by the combination of Methylprednisolone and Levalbuterol.	Asthma [CA23]	[32]
Pirbuterol	DMI5678	Minor	Increased risk of hypokalemia by the combination of Methylprednisolone and Pirbuterol.	Asthma [CA23]	[36]
Salbutamol	DMN9CWF	Minor	Increased risk of hypokalemia by the combination of Methylprednisolone and Salbutamol.	Asthma [CA23]	[32]
Roflumilast	DMPGHY8	Moderate	Additive immunosuppressive effects by the combination of Methylprednisolone and Roflumilast.	Asthma [CA23]	[37]
Formoterol	DMSOURV	Minor	Increased risk of hypokalemia by the combination of Methylprednisolone and Formoterol.	Asthma [CA23]	[36]
Ofloxacin	DM0VQN3	Major	Increased risk of tendinitis/tendon rupture by the combination of Methylprednisolone and Ofloxacin.	Bacterial infection [1A00-1C4Z]	[38]
Dalfopristin	DM4LTKV	Moderate	Decreased metabolism of Methylprednisolone caused by Dalfopristin mediated inhibition of CYP450 enzyme.	Bacterial infection [1A00-1C4Z]	[39]
Clarithromycin	DM4M1SG	Major	Decreased metabolism of Methylprednisolone caused by Clarithromycin mediated inhibition of CYP450 enzyme.	Bacterial infection [1A00-1C4Z]	[36]
Sparfloxacin	DMB4HCT	Major	Increased risk of tendinitis/tendon rupture by the combination of Methylprednisolone and Sparfloxacin.	Bacterial infection [1A00-1C4Z]	[38]
Gemifloxacin	DMHT34O	Major	Increased risk of tendinitis/tendon rupture by the combination of Methylprednisolone and Gemifloxacin.	Bacterial infection [1A00-1C4Z]	[38]
Norfloxacin	DMIZ6W2	Major	Increased risk of tendinitis/tendon rupture by the combination of Methylprednisolone and Norfloxacin.	Bacterial infection [1A00-1C4Z]	[38]
ABT-492	DMJFD2I	Major	Increased risk of tendinitis/tendon rupture by the combination of Methylprednisolone and ABT-492.	Bacterial infection [1A00-1C4Z]	[38]
Levofloxacin	DMS60RB	Major	Increased risk of tendinitis/tendon rupture by the combination of Methylprednisolone and Levofloxacin.	Bacterial infection [1A00-1C4Z]	[38]
Troleandomycin	DMUZNIG	Major	Decreased metabolism of Methylprednisolone caused by Troleandomycin mediated inhibition of CYP450 enzyme.	Bacterial infection [1A00-1C4Z]	[36]
Lomefloxacin	DMVRH9C	Major	Increased risk of tendinitis/tendon rupture by the combination of Methylprednisolone and Lomefloxacin.	Bacterial infection [1A00-1C4Z]	[38]
Telithromycin	DMZ4P3A	Major	Decreased metabolism of Methylprednisolone caused by Telithromycin mediated inhibition of CYP450 enzyme.	Bacterial infection [1A00-1C4Z]	[36]
Lapatinib	DM3BH1Y	Moderate	Decreased metabolism of Methylprednisolone caused by Lapatinib mediated inhibition of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[40]
Tucatinib	DMBESUA	Major	Decreased metabolism of Methylprednisolone caused by Tucatinib mediated inhibition of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[36]
Vilanterol	DMF5EK1	Minor	Increased risk of hypokalemia by the combination of Methylprednisolone and Vilanterol.	Chronic obstructive pulmonary disease [CA22]	[32]
Indacaterol	DMQJHR7	Minor	Increased risk of hypokalemia by the combination of Methylprednisolone and Indacaterol.	Chronic obstructive pulmonary disease [CA22]	[36]
Arformoterol	DMYM974	Minor	Increased risk of hypokalemia by the combination of Methylprednisolone and Arformoterol.	Chronic obstructive pulmonary disease [CA22]	[36]
Ketoprofen	DMRKXPT	Moderate	Increased risk of GI mucosal injury/bleeding risk by the combination of Methylprednisolone and Ketoprofen.	Chronic pain [MG30]	[41]
Isoproterenol	DMK7MEY	Minor	Increased risk of hypokalemia by the combination of Methylprednisolone and Isoproterenol.	Conduction disorder [BC63]	[32]
Pancuronium	DMB0VY8	Moderate	Additive neuromuscular blocking effects by the combination of Methylprednisolone and Pancuronium.	Corneal disease [9A76-9A78]	[36]
Tubocurarine	DMBZIVP	Moderate	Additive neuromuscular blocking effects by the combination of Methylprednisolone and Tubocurarine.	Corneal disease [9A76-9A78]	[36]
Ivacaftor	DMZC1HS	Moderate	Decreased clearance of Methylprednisolone due to the transporter inhibition by Ivacaftor.	Cystic fibrosis [CA25]	[42]
MK-8228	DMOB58Q	Moderate	Decreased metabolism of Methylprednisolone caused by MK-8228 mediated inhibition of CYP450 enzyme.	Cytomegaloviral disease [1D82]	[43]
Nefazodone	DM4ZS8M	Major	Decreased metabolism of Methylprednisolone caused by Nefazodone mediated inhibition of CYP450 enzyme.	Depression [6A70-6A7Z]	[36]
Stiripentol	DMMSDOY	Moderate	Decreased metabolism of Methylprednisolone caused by Stiripentol mediated inhibition of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[44]
Fosphenytoin	DMOX3LB	Moderate	Increased metabolism of Methylprednisolone caused by Fosphenytoin mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[45]
Phenobarbital	DMXZOCG	Moderate	Increased metabolism of Methylprednisolone caused by Phenobarbital mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[46]
Tazemetostat	DMWP1BH	Moderate	Increased metabolism of Methylprednisolone caused by Tazemetostat mediated induction of CYP450 enzyme.	Follicular lymphoma [2A80]	[47]
Itraconazole	DMCR1MV	Major	Decreased metabolism of Methylprednisolone caused by Itraconazole mediated inhibition of CYP450 enzyme.	Fungal infection [1F29-1F2F]	[36]
Ketoconazole	DMPZI3Q	Major	Decreased metabolism of Methylprednisolone caused by Ketoconazole mediated inhibition of CYP450 enzyme.	Fungal infection [1F29-1F2F]	[36]
Boceprevir	DMBSHMF	Major	Decreased metabolism of Methylprednisolone caused by Boceprevir mediated inhibition of CYP450 enzyme.	Hepatitis virus infection [1E50-1E51]	[36]
Telaprevir	DMMRV29	Major	Decreased metabolism of Methylprednisolone caused by Telaprevir mediated inhibition of CYP450 enzyme.	Hepatitis virus infection [1E50-1E51]	[36]
Rifampin	DMA8J1G	Moderate	Increased metabolism of Methylprednisolone caused by Rifampin mediated induction of CYP450 enzyme.	HIV-infected patients with tuberculosis [1B10-1B14]	[48]
Rifapentine	DMCHV4I	Moderate	Increased metabolism of Methylprednisolone caused by Rifapentine mediated induction of CYP450 enzyme.	HIV-infected patients with tuberculosis [1B10-1B14]	[49]
Fosamprenavir	DM4W9B3	Major	Decreased metabolism of Methylprednisolone caused by Fosamprenavir mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[36]
Cobicistat	DM6L4H2	Major	Decreased metabolism of Methylprednisolone caused by Cobicistat mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[36]
Saquinavir	DMG814N	Major	Decreased metabolism of Methylprednisolone caused by Saquinavir mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[36]
Darunavir	DMN3GCH	Moderate	Decreased metabolism of Methylprednisolone caused by Darunavir mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[36]
Atazanavir	DMSYRBX	Major	Decreased metabolism of Methylprednisolone caused by Atazanavir mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[36]
Bempedoic acid	DM1CI9R	Major	Increased risk of tendinitis/tendon rupture by the combination of Methylprednisolone and Bempedoic acid.	Hyper-lipoproteinaemia [5C80]	[50]
Teriflunomide	DMQ2FKJ	Major	Additive immunosuppressive effects by the combination of Methylprednisolone and Teriflunomide.	Hyper-lipoproteinaemia [5C80]	[51]
Berotralstat	DMWA2DZ	Moderate	Decreased metabolism of Methylprednisolone caused by Berotralstat mediated inhibition of CYP450 enzyme.	Innate/adaptive immunodeficiency [4A00]	[52]
Amobarbital	DM0GQ8N	Moderate	Increased metabolism of Methylprednisolone caused by Amobarbital mediated induction of CYP450 enzyme.	Insomnia [7A00-7A0Z]	[46]
Denosumab	DMNI0KO	Moderate	Additive immunosuppressive effects by the combination of Methylprednisolone and Denosumab.	Low bone mass disorder [FB83]	[53]
PF-06463922	DMKM7EW	Moderate	Increased metabolism of Methylprednisolone caused by PF-06463922 mediated induction of CYP450 enzyme.	Lung cancer [2C25]	[54]
Selpercatinib	DMZR15V	Moderate	Decreased metabolism of Methylprednisolone caused by Selpercatinib mediated inhibition of CYP450 enzyme.	Lung cancer [2C25]	[37]
Idelalisib	DM602WT	Major	Decreased metabolism of Methylprednisolone caused by Idelalisib mediated inhibition of CYP450 enzyme.	Mature B-cell leukaemia [2A82]	[36]
IPI-145	DMWA24P	Moderate	Decreased metabolism of Methylprednisolone caused by IPI-145 mediated inhibition of CYP450 enzyme.	Mature B-cell leukaemia [2A82]	[55]
Nivolumab	DMAB9QE	Moderate	Additive immunosuppressive effects by the combination of Methylprednisolone and Nivolumab.	Melanoma [2C30]	[36]
Pembrolizumab	DMFQEA6	Moderate	Additive immunosuppressive effects by the combination of Methylprednisolone and Pembrolizumab.	Melanoma [2C30]	[36]
Ipilimumab	DMJTIYK	Moderate	Additive immunosuppressive effects by the combination of Methylprednisolone and Ipilimumab.	Melanoma [2C30]	[36]
Cemiplimab	DMKMJHE	Moderate	Additive immunosuppressive effects by the combination of Methylprednisolone and Cemiplimab.	Melanoma [2C30]	[36]
Dabrafenib	DMX6OE3	Moderate	Increased metabolism of Methylprednisolone caused by Dabrafenib mediated induction of CYP450 enzyme.	Melanoma [2C30]	[37]
Thalidomide	DM70BU5	Major	Additive thrombogenic effects by the combination of Methylprednisolone and Thalidomide.	Multiple myeloma [2A83]	[56]
Tecfidera	DM2OVDT	Moderate	Additive immunosuppressive effects by the combination of Methylprednisolone and Tecfidera.	Multiple sclerosis [8A40]	[57]
Siponimod	DM2R86O	Major	Additive immunosuppressive effects by the combination of Methylprednisolone and Siponimod.	Multiple sclerosis [8A40]	[32]
Fingolimod	DM5JVAN	Major	Additive immunosuppressive effects by the combination of Methylprednisolone and Fingolimod.	Multiple sclerosis [8A40]	[58]
Ocrelizumab	DMEZ2KH	Moderate	Additive immunosuppressive effects by the combination of Methylprednisolone and Ocrelizumab.	Multiple sclerosis [8A40]	[59]
Ozanimod	DMT6AM2	Major	Additive immunosuppressive effects by the combination of Methylprednisolone and Ozanimod.	Multiple sclerosis [8A40]	[37]
Fedratinib	DM4ZBK6	Moderate	Decreased metabolism of Methylprednisolone caused by Fedratinib mediated inhibition of CYP450 enzyme.	Myeloproliferative neoplasm [2A20]	[36]
Omacetaxine mepesuccinate	DMPU2WX	Moderate	Additive immunosuppressive effects by the combination of Methylprednisolone and Omacetaxine mepesuccinate.	Myeloproliferative neoplasm [2A20]	[60]
Bupropion	DM5PCS7	Major	Increased risk of lowers seizure threshold by the combination of Methylprednisolone and Bupropion.	Nicotine use disorder [6C4A]	[61]
Atezolizumab	DMMF8U0	Moderate	Additive immunosuppressive effects by the combination of Methylprednisolone and Atezolizumab.	Non-small cell lung cancer [2C25]	[36]
Rucaparib	DM9PVX8	Moderate	Decreased metabolism of Methylprednisolone caused by Rucaparib mediated inhibition of CYP450 enzyme.	Ovarian cancer [2C73]	[62]
Ibuprofen	DM8VCBE	Moderate	Increased risk of GI mucosal injury/bleeding risk by the combination of Methylprednisolone and Ibuprofen.	Pain [MG30-MG3Z]	[41]
Abametapir	DM2RX0I	Moderate	Decreased metabolism of Methylprednisolone caused by Abametapir mediated inhibition of CYP450 enzyme.	Pediculosis [1G00]	[63]
Lefamulin	DME6G97	Moderate	Decreased metabolism of Methylprednisolone caused by Lefamulin mediated inhibition of CYP450 enzyme.	Pneumonia [CA40]	[64]
Choline salicylate	DM8P137	Moderate	Increased risk of GI mucosal injury/bleeding risk by the combination of Methylprednisolone and Choline salicylate.	Postoperative inflammation [1A00-CA43]	[65]
Bromfenac	DMKB79O	Moderate	Increased risk of GI mucosal injury/bleeding risk by the combination of Methylprednisolone and Bromfenac.	Postoperative inflammation [1A00-CA43]	[41]
Lonafarnib	DMGM2Z6	Major	Decreased metabolism of Methylprednisolone caused by Lonafarnib mediated inhibition of CYP450 enzyme.	Premature ageing appearance [LD2B]	[36]
Temsirolimus	DMS104F	Moderate	Increased plasma concentrations of Methylprednisolone and Temsirolimus due to competitive inhibition of the same metabolic pathway.	Renal cell carcinoma [2C90]	[66]
Gatifloxacin	DMSL679	Major	Increased risk of tendinitis/tendon rupture by the combination of Methylprednisolone and Gatifloxacin.	Respiratory infection [CA07-CA4Z]	[38]
Salsalate	DM13P4C	Moderate	Increased risk of GI mucosal injury/bleeding risk by the combination of Methylprednisolone and Salsalate.	Rheumatoid arthritis [FA20]	[65]
Canakinumab	DM8HLO5	Moderate	Additive immunosuppressive effects by the combination of Methylprednisolone and Canakinumab.	Rheumatoid arthritis [FA20]	[67]
Oxaprozin	DM9UB0P	Moderate	Increased risk of GI mucosal injury/bleeding risk by the combination of Methylprednisolone and Oxaprozin.	Rheumatoid arthritis [FA20]	[41]
Rilonacept	DMGLUQS	Moderate	Additive immunosuppressive effects by the combination of Methylprednisolone and Rilonacept.	Rheumatoid arthritis [FA20]	[67]
Golimumab	DMHZV7X	Major	Additive immunosuppressive effects by the combination of Methylprednisolone and Golimumab.	Rheumatoid arthritis [FA20]	[68]
Leflunomide	DMR8ONJ	Major	Additive immunosuppressive effects by the combination of Methylprednisolone and Leflunomide.	Rheumatoid arthritis [FA20]	[51]
Anthrax vaccine	DM9GSWY	Moderate	Antagonize the effect of Methylprednisolone when combined with Anthrax vaccine.	Sepsis [1G40-1G41]	[69]
Voxelotor	DMCS6M5	Moderate	Decreased metabolism of Methylprednisolone caused by Voxelotor mediated inhibition of CYP450 enzyme.	Sickle-cell disorder [3A51]	[36]
Telotristat ethyl	DMDIYFZ	Moderate	Increased metabolism of Methylprednisolone caused by Telotristat ethyl mediated induction of CYP450 enzyme.	Small intestine developmental anomaly [DA90]	[37]
Pitolisant	DM8RFNJ	Moderate	Increased risk of GI mucosal injury/bleeding risk by the combination of Methylprednisolone and Pitolisant.	Somnolence [MG42]	[37]
Fostamatinib	DM6AUHV	Moderate	Decreased metabolism of Methylprednisolone caused by Fostamatinib mediated inhibition of CYP450 enzyme.	Thrombocytopenia [3B64]	[70]
Doxacurium	DMKE7L9	Moderate	Additive neuromuscular blocking effects by the combination of Methylprednisolone and Doxacurium.	Tonus and reflex abnormality [MB47]	[36]
Vecuronium	DMP0UK2	Moderate	Additive neuromuscular blocking effects by the combination of Methylprednisolone and Vecuronium.	Tonus and reflex abnormality [MB47]	[36]
Durvalumab	DM4PVDY	Moderate	Additive immunosuppressive effects by the combination of Methylprednisolone and Durvalumab.	Ureteral cancer [2C92]	[36]
-----------


⏷ Show the Full List of 92 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG

DIG Name	DIG ID	PubChem CID	Functional Classification
Sodium lauryl sulfate	E00464	3423265	Emulsifying agent; Modified-release agent; Penetration agent; Solubilizing agent; Surfactant; lubricant
Stearic acid	E00079	5281	Emulsifying agent; Solubilizing agent; Viscosity-controlling agent; lubricant
Sunset yellow FCF	E00255	17730	Colorant
Beta-D-lactose	E00099	6134	Diluent; Dry powder inhaler carrier; Lyophilization aid
Calcium stearate	E00244	15324	lubricant
Carmellose sodium	E00625	Not Available	Disintegrant
Lactose monohydrate	E00393	104938	Binding agent; Diluent; Dry powder inhaler carrier; Lyophilization aid
Magnesium stearate	E00208	11177	lubricant
Saccharose	E00091	5988	Binding agent; Coating agent; Cryoprotectant; Diluent; Flavoring agent; Suspending agent; Viscosity-controlling agent
Silicon dioxide	E00670	Not Available	Anticaking agent; Opacifying agent; Viscosity-controlling agent
Sorbic acid	E00441	643460	Antimicrobial preservative
--------------------


⏷ Show the Full List of 11 Pharmaceutical Excipients of This Drug

Pharmaceutical Formulation

Formulation Name	Drug Dosage	Dosage Form	Route
Methylprednisolone 4 mg tablet	4 mg	Oral Tablet	Oral
Methylprednisolone 2 mg tablet	2 mg	Oral Tablet	Oral
Methylprednisolone 16 mg tablet	16 mg	Oral Tablet	Oral
Methylprednisolone 32 mg tablet	32 mg	Oral Tablet	Oral
Methylprednisolone 8 mg tablet	8 mg	Oral Tablet	Oral

Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
2	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7088).
3	BDDCS applied to over 900 drugs
4	Critical Evaluation of Human Oral Bioavailability for Pharmaceutical Drugs by Using Various Cheminformatics Approaches
5	Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
6	Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
7	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
8	Secretory transport of methylprednisolone possibly mediated by P-glycoprotein in Caco-2 cells. Biol Pharm Bull. 2002 Mar;25(3):393-6.
9	Cytochrome P450 enzyme regulation by glucocorticoids and consequences in terms of drug interaction. Expert Opin Drug Metab Toxicol. 2014 Mar;10(3):425-35.
10	Expression levels and activation of a PXR variant are directly related to drug resistance in osteosarcoma cell lines. Cancer. 2007 Mar 1;109(5):957-65.
11	Contribution of human hepatic cytochrome P450 isoforms to regioselective hydroxylation of steroid hormones. Xenobiotica. 1998 Jun;28(6):539-47.
12	Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther. 2004 Sep;310(3):1062-75.
13	Isoform-specific regulation of cytochromes P450 expression by estradiol and progesterone. Drug Metab Dispos. 2013 Feb;41(2):263-9.
14	Metabolic interactions between acetaminophen (paracetamol) and two flavonoids, luteolin and quercetin, through in-vitro inhibition studies. J Pharm Pharmacol. 2017 Dec;69(12):1762-1772.
15	Potent mechanism-based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates. Br J Pharmacol. 2012 Apr;165(8):2787-98.
16	Effects of morin on the pharmacokinetics of etoposide in rats. Biopharm Drug Dispos. 2007 Apr;28(3):151-6.
17	The metabolism of zidovudine by human liver microsomes in vitro: formation of 3'-amino-3'-deoxythymidine. Biochem Pharmacol. 1994 Jul 19;48(2):267-76.
18	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
19	Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
20	MDR1 (ABCB1) G1199A (Ser400Asn) polymorphism alters transepithelial permeability and sensitivity to anticancer agents. Cancer Chemother Pharmacol. 2009 Jun;64(1):183-8.
21	Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
22	Folate transporter expression decreases in the human placenta throughout pregnancy and in pre-eclampsia. Pregnancy Hypertens. 2012 Apr;2(2):123-31.
23	Comparative studies on in vitro methods for evaluating in vivo function of MDR1 P-glycoprotein. Pharm Res. 2001 Dec;18(12):1660-8.
24	Antiestrogens and steroid hormones: substrates of the human P-glycoprotein. Biochem Pharmacol. 1994 Jul 19;48(2):287-92.
25	Association of genetic polymorphisms in the influx transporter SLCO1B3 and the efflux transporter ABCB1 with imatinib pharmacokinetics in patients with chronic myeloid leukemia. Ther Drug Monit. 2011 Apr;33(2):244-50.
26	Interaction between the glucocorticoid and erythropoietin receptors in human erythroid cells. Exp Hematol. 2009 May;37(5):559-72.
27	Aldosterone (mineralocorticoid) equivalent to prednisolone (glucocorticoid) in reversing hearing loss in MRL/MpJ-Fas1pr autoimmune mice. Laryngoscope. 2000 Nov;110(11):1902-6.
28	Fluticasone furoate nasal spray in allergic rhinitis. Drugs Today (Barc). 2008 Apr;44(4):251-60.
29	Cytochromes P450 (CYP) in the Poeciliopsis lucida hepatocellular carcinoma cell line (PLHC-1): dose- and time-dependent glucocorticoid potentiation of CYP1A induction without induction of CYP3A. ArchBiochem Biophys. 1996 May 1;329(1):113-22.
30	PXR-mediated induction of human CYP3A4 and mouse Cyp3a11 by the glucocorticoid budesonide. Eur J Pharm Sci. 2009 Mar 2;36(4-5):565-71.
31	The glucocorticoid agonist activities of mifepristone (RU486) and progesterone are dependent on glucocorticoid receptor levels but not on EC50 values. Steroids. 2007 Jun;72(6-7):600-8.
32	Cerner Multum, Inc. "Australian Product Information.".
33	Doherty MM, Charman WN "The mucosa of the small intestine: how clinically relevant as an organ of drug metabolism?" Clin Pharmacokinet 41 (2002): 235-53. [PMID: 11978143]
34	DSouza DL, Levasseur LM, Nezamis J, Robbins DK, Simms L, Koch KM "Effect of alosetron on the pharmacokinetics of alprazolam." J Clin Pharmacol 41 (2001): 452-4. [PMID: 11304902]
35	Albin H, Vincon G, Demotes-Mainard F, et al "Effect of aluminium phosphate on the bioavailability of cimetidine and prednisolone." Eur J Clin Pharmacol 26 (1984): 271-3. [PMID: 6723769]
36	Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare "Centro de informacion online de medicamentos de la AEMPS - CIMA.".
37	Cerner Multum, Inc. "UK Summary of Product Characteristics.".
38	FDA. U.S. Food and Drug Administration "Information for Healthcare Professionals. Fluoroquinolone Antimicrobial Drugs. FDA Alert [7/8/2008].".
39	Product Information. Synercid (dalfopristin-quinupristin) Rhone-Poulenc Rorer, Collegeville, PA.
40	Product Information. Tykerb (lapatinib). Novartis Pharmaceuticals, East Hanover, NJ.
41	Buchman AL, Schwartz MR "Colonic ulceration associated with the systemic use of nonsteroidal antiinflammatory medication." J Clin Gastroenterol 22 (1996): 224-6. [PMID: 8724264]
42	Product Information. Kalydeco (ivacaftor). Vertex Pharmaceuticals, Cambridge, MA.
43	Product Information. Prevymis (letermovir). Merck & Company Inc, Whitehouse Station, NJ.
44	EMEA. European Medicines Agency "EPARs. European Union Public Assessment Reports.".
45	Frey BM, Frey FJ "Phenytoin modulates the pharmacokinetics of prednisolone and the pharmacodynamics of prednisolone as assessed by the inhibition of the mixed lymphocyte reaction in humans." Eur J Clin Invest 14 (1984): 1-6. [PMID: 6230241]
46	Bartoszek M, Brenner AM, Szefler SJ "Prednisolone and methylprednisolone kinetics in children receiving anticonvulsant therapy." Clin Pharmacol Ther 42 (1987): 424-32. [PMID: 3665340]
47	Product Information. Tazverik (tazemetostat). Epizyme, Inc, Cambridge, MA.
48	Kyriazopoulou V, Parparousi O, Vagenakis AG "Rifampicin-induced adrenal crisis in Addisonian patients receiving corticosteroid replacement therapy." J Clin Endocrinol Metab 59 (1984): 1204-6. [PMID: 6490796]
49	Product Information. Priftin (rifapentine). Hoechst Marion-Roussel Inc, Kansas City, MO.
50	Product Information. Nexletol (bempedoic acid). Esperion Therapeutics, Ann Arbor, MI.
51	Product Information. Arava (leflunomide). Hoechst Marion-Roussel Inc, Kansas City, MO.
52	Product Information. Orladeyo (berotralstat). BioCryst Pharmaceuticals Inc, Durham, NC.
53	Product Information. Prolia (denosumab). Amgen USA, Thousand Oaks, CA.
54	Product Information. Lorbrena (lorlatinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
55	Product Information. Copiktra (duvelisib). Verastem, Inc., Needham, MA.
56	Bennett CL, Nebeker JR, Samore MH, et al "The Research on Adverse Drug Events and Reports (RADAR) project." JAMA 293 (2005): 2131-40. [PMID: 15870417]
57	Product Information. Vumerity (diroximel fumarate). Alkermes, Inc, Cambridge, MA.
58	Product Information. Gilenya (fingolimod). Novartis Pharmaceuticals, East Hanover, NJ.
59	Product Information. Ocrevus (ocrelizumab). Genentech, South San Francisco, CA.
60	Product Information. Synribo (omacetaxine). Teva Pharmaceuticals USA, North Wales, PA.
61	Product Information. Wellbutrin XL (buPROPion). GlaxoSmithKline, Philadelphia, PA.
62	EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring.".
63	Product Information. Xeglyze (abametapir topical). Dr. Reddy's Laboratories Inc, Upper Saddle River, NJ.
64	Product Information. Xenleta (lefamulin). Nabriva Therapeutics US, Inc., King of Prussia, PA.
65	Baer PA, Shore A, Ikeman RL "Transient fall in serum salicylate levels following intraarticular injection of steroid in patients with rheumatoid arthritis." Arthritis Rheum 30 (1987): 345-7. [PMID: 3566826]
66	Product Information. Prograf (tacrolimus). Fujisawa, Deerfield, IL.
67	Product Information. Arcalyst (rilonacept). Regeneron Pharmaceuticals Inc, Tarrytown, NY.
68	Product Information. Cimzia (certolizumab). UCB Pharma Inc, Smyrna, GA.
69	CDC. Centers for Disease Control and Prevention/ "Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence." MMWR Morb Mortal Wkly Rep 42(RR-04) (1993): 1-18. [PMID: 20300058]
70	Product Information. Tavalisse (fostamatinib). Rigel Pharmaceuticals, South San Francisco, CA.